Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 21;14(22):5706.
doi: 10.3390/cancers14225706.

COVID-19 and Lung Cancer Survival: An Updated Systematic Review and Meta-Analysis

Simone Oldani  1 , Fausto Petrelli  1 , Giuseppina Dognini  1 , Karen Borgonovo  1 , Maria Chiara Parati  1 , Mara Ghilardi  1 , Lorenzo Dottorini  1 , Mary Cabiddu  1 , Andrea Luciani  1
Affiliations
Review

COVID-19 and Lung Cancer Survival: An Updated Systematic Review and Meta-Analysis

Simone Oldani et al. Cancers (Basel). .

Abstract

Introduction: The outbreak of COVID-19 poses an unprecedented challenge to global public health. Patients with cancer are at a higher risk during the SARS-CoV-2 pandemic. Patients with lung cancer and COVID-19 were compared to those without cancer and those with other malignancies for the main outcome of this study. The aim of this study was to evaluate the differences in susceptibility, disease severity, and mortality between lung cancer patients and the general population. Methods: Using PRISMA reporting guidelines, we conducted a systematic review and meta-analysis of the published literature. The Cochrane Library database, PubMed, EMBASE, and PubMed Central were comprehensively searched for published papers until 31 May 2022. A pooled risk ratio (OR) with 95% CI was presented as the result of this meta-analysis. Results: We included 29 studies involved 21,257 patients with lung cancer and SARS-CoV-2 infection. Analysis data showed that mortality in patients with lung cancer was significantly higher than that in patients without cancer (HR = 2.00 [95%CI 1.52, 2.63], p < 0.01) or with other malignancies (HR = 1.91 [95%CI 1.53, 2.39], p < 0.01). In addition, we also observed a higher risk of severe infection in terms of life-threatening or required ICU admission/mechanical ventilation for lung cancer patients (HR = 1.47 [95%CI 1.06, 2.03], p = 0.02) than for patients with no cancer or other malignancies. Regarding lung cancer as a risk factor for acquiring SARS-CoV-2 infection, we could not reach statistical significance (hazard ratio [HR] =2.73 [95%CI 0.84, 8.94], p = 0.1). Conclusion: Lung cancer represents an important comorbidity and modifies COVID-19 prognosis in terms of disease severity and mortality. More patients experience severe or even fatal events. Considering their inherent fragility, patients with lung cancer, and generally all oncological populations, should be treated more carefully during the COVID-19 pandemic.

Keywords: COVID-19; lung cancer; meta-analysis; mortality; risk.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of included studies.
Figure 2
Figure 2
Forest plot for risk of infection in lung cancer patients.
Figure 3
Figure 3
Forest plot for risk of severe infection in lung cancer patients.
Figure 4
Figure 4
Forest plot for risk of mortality in lung cancer patients.
Figure 5
Figure 5
Forest plot for risk of mortality in lung cancer compared with other malignancies.
See this image and copyright information in PMC

References

    1. Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;13:782–793. doi: 10.1001/jama.2020.12839. - DOI - PubMed
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
    1. Addeo A., Friedlaender A. Cancer and COVID-19: Unmasking their ties. Cancer Treat. Rev. 2020;88:102041. doi: 10.1016/j.ctrv.2020.102041. - DOI - PMC - PubMed
    1. Xiong B., Liu T., Luo P., Wei Y., Zhou Y., Liu M., Zhang Y., Wang H., Zhang X., Wang X., et al. Prominent Hypercoagulability Associated With Inflammatory State Among Cancer Patients With SARS-CoV-2 Infection. Front. Oncol. 2020;10:1345. doi: 10.3389/fonc.2020.01345. - DOI - PMC - PubMed
    1. Shieh W.-J., Hsiao C.-H., Paddock C.D., Guarner J., Goldsmith C.S., Tatti K., Packard M., Mueller L., Wu M.-Z., Rollin P., et al. Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan. Hum. Pathol. 2005;36:303–309. doi: 10.1016/j.humpath.2004.11.006. - DOI - PMC - PubMed